Breakthroughs for Patients, CMC Regulatory Flexibility
This article was originally published in The Gold Sheet
Executive Summary
By compressing clinical timelines, a FDASIA-mandated “breakthrough therapy” application process is pressuring FDA and industry to complete CMC reviews much more quickly. While FDA is emphasizing starting earlier and working harder, industry is talking more about the possibility of deferring some CMC activities post-submission or post-approval.